csirt@kutim:~/threat-intel/cve/CVE-2025-57203

Katalog CVE

CVSS 4.8 · Medium EPSS 0,24%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada liquidlabs magicai. Skor CVSS 3.1 4.8 (Medium) menurut CISA ADP.

Deskripsi (NVD)

MagicProject AI version 9.1 is affected by a Cross-Site Scripting (XSS) vulnerability within the chatbot generation feature available to authenticated admin users. The vulnerability resides in the prompt parameter submitted to the /dashboard/user/generator/generate-stream endpoint via a multipart/form-data POST request. Due to insufficient input sanitization, attackers can inject HTML-based JavaScript payloads. This payload is stored and rendered unsanitized in subsequent views, leading to execution in other users' browsers when they access affected content. This issue allows an authenticated attacker to execute arbitrary JavaScript in the context of another user, potentially leading to session hijacking, privilege escalation, data exfiltration, or administrative account takeover. The application does not implement a Content Security Policy (CSP) or adequate input filtering to prevent such attacks. A fix should include proper sanitization, output encoding, and strong CSP enforcement to mitigate exploitation.

Rincian

Terbit di NVD
22 September 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
4.8 (Medium), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,24% peluang dieksploitasi; lebih tinggi dari 13,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
liquidlabs magicai Versi 9.1

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.